T2* relaxometry maps of the uterus – Future prospectives with oncology implications

Roxana M Pintican1*; Reka David Kerekes2; Vlad Bura3; Florin Stamatian3; Tunde Kovacs4; Iris Morar5; Viorica Nagy6; Radu Fechete6; Angelica Chioarcan7

1“Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania, Radiology and Medical Imaging, County Emergency Hospital Radiology Department, Cluj-Napoca, Romania.
2Radiology and Medical Imaging, County Emergency Hospital Radiology Department, Clinicilor Str. 3-5, 400009, Cluj-Napoca, Romania.
3“Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania, Chief of the Obstetrics and Gynecology Department, County Emergency Hospital, Clinicilor Str. 3-5, 400009, Cluj-Napoca, Romania.
4Obstetrics and Gynecology Department at IMOGEN Research Center, County Emergency Hospital, L. Pasteur Str., 400349, Cluj-Napoca, Romania.
5Physicist, IMOGEN Research Center, County Emergency Hospital, L. Pasteur Str., 400349, Cluj-Napoca, Romania.
6“Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania; “Ion Chiricuta” Oncology Institute, Republicii Str 34-36, 400015, Cluj-Napoca, Romania.
7professor at Technic University, Physics and Chemistry Department, G Baritiu Str. 25, 400027, Cluj-Napoca, Romania.
8“Iuliu Hatieganu” University of Medicine and Pharmacy, Department of Radiology, Cluj-Napoca, Romania.

*Corresponding Author: Roxana M Pintican
“Iuliu Hatieganu” University of Medicine and Pharmacy, Department of Radiology, Cluj-Napoca, Romania; Radiology and Medical Imaging, County Emergency Hospital Radiology Department, Clinicilor Str. 3-5, 400009, Cluj-Napoca, Romania. Email: roxana.pintican@gmail.com

Abstract

T2* relaxometry mapping has found diverse applications in neuro-radiology but was insufficiently evaluated in pelvis MRI. Further, staging of the uterine-related cancers may be sometimes a cumbersome.

Our aim is to present the T2* relaxometry maps respectively relaxometry and proton density values in patients with endometrial and cervical cancer, together with their postoperative outcomes.

Three patients with uterine-related cancers underwent a 3T pelvic MRI examination. The protocol included a large field-of-view (FOV = 28 cm), a short (TE=30 ms) and a long (TE = 200 ms) echo time sequences. T2* maps were obtained by the means of post-processing methods.

Parametric maps showed same Relaxation Time (RT) between endometrial cancer and adjacent metastatic lymphadenopathy, respectively different RT between endometrial and cervical cancer.

In conclusion, we presented the T2* relaxometry values of endometrial and cervical cancer, and discuss their possible implications in FIGO staging and patient management.

Keywords: T2 relaxometry; T2 mapping; MRI; Endometrial cancer; Cervical cancer; FIGO staging.
**Introduction**

In the era of multiparametric Magnetic Resonance Imaging (MRI), the T2 relaxometry is gaining more and more credibility and usefulness. T2 parametric maps found varied application in neuroradiology, being able to improve detection of epileptogenic zones in hippocampus, as a neuroimaging marker in Friedreich’s ataxia and even in infectious diseases such as cysticercosis [1-3].

Cardiac and musculoskeletal imaging likewise, proved to be enriched by using T2 parametric maps, in the characterization of acute myocardial infarction or cartilage damage after ACL reconstruction [4,5].

Regarding the branch of women imaging, the relaxometry maps are promising in both lesion detection and characterization. Studies concluded that T2 relaxation time was significantly lower in invasive breast cancers than DCIS (ductal carcinoma in situ) and more than that, patients with invasive type had lower T2 time in higher histologic grade [6]. Furthermore, T2 maps revealed shorter time for responders versus non-responders after neoadjuvant chemotherapy, thus being useful in appreciating tumor apoptosis [7]. A recent paper, highlighted a new method of MRI fingerprinting technique, which allows breast lesions diagnostic using volumetric quantification of T1 and T2 relaxation time [8].

T2 relaxometry studies focused on the pelvis area, are still at the beginning. Imaoka et al have previously demonstrated the layered uterine structure and Ghosh et al emphasized the use of the T2 maps in diagnostic of endometrial cancer and adenomyosis, with a protocol that included multiple TE (echo time) per patient /acquisition [9,10].

To the best of our knowledge, there are no MRI relaxometry studies on cervical cancer, or related to endometrial or cervical cancer staging. Furthermore, MRI was recently included as a mandatory pre-operative diagnostic tool in patients with endometrial cancer, allowing patient stratification and guiding the surgical planning [11].

Subsequently, our aim is to evaluate oncologic patients using a T2 relaxometry map of the whole pelvis, obtained with only two different TE’s. Related to future prospective with oncology implication, we will exhibit the T2 relaxometry map of cancer area, lymph nodes and nearby structures with pathology correlation.

**Case series**

Three oncologic patients (two with endometrial cancer and one with cervical cancer) underwent a 3T MRI (Discovery MR750w, GE) examination using a body coil transmission and a 16-channel phased-array receiver. The MRI protocol included 2 different TE (TE1=30 ms and TE2=200 ms), with a long repetition time (TR=5000 ms) and a large field-of-view (FOV=28 cm). We decided on using only 2 different TE’s, due to the short examination time, and also because it minimize the motion artifacts.

An in-house dedicated software written in Processing™ was used to calculate the T2 relaxation time for each manually defined areas of interest. T2 relaxometry and proton density maps of the entire pelvis were obtained.

We analyzed the pathologic endometrium and cervix, pelvic lymphadenopathies, and a section of small bowel and rectum that were related to the cancer area. In concordance with international oncology recommendations, FIGO staging system was used for staging endometrial and cervical cancer patients [12,13].

**Case 1**

A 67y old patient, with endometrial curettage positive for cancer. While bilateral iliac lymph nodes have suspicious T2 characteristics (round shape, inhomogeneous), the left para-uterine lymph node has uncertain features (oval, homogeneous) on both T2 and DWI (no restricted diffusion). On T2* relaxometry map, the lymph node exhibits similar relaxation time as the endometrial cancer. The postoperative pathology revealed positive endometrial cancer cells, grade 2 within all 3 lymph nodes and a stage IIIC1 was attributed to the patient (Figure 1 & 2).

![Figure 1: Upper images: Axial T2 with TE=30ms (left) and TE=200ms (right). Lower images: Proton density map (left) and T2* relaxometry map (right). Enlarged and distended endometrial cavity, due to a solid mass proven to be endometrial cancer. Left parauterine lymph node with uncertain malignant potential (arrow).](image1)

![Figure 2: Manually defined areas of interest: endometrial cancer (top) and left parauterine lymph node (bottom). The grey box on the right side of each image shows the automatic statistical analyses: Minimum, maximum and average T2* relaxometry time (T2 min, T2 max, T2 av) and proton density values (1Hmin, 1Hmax, 1H av). Endometrial cancer and left lymph node show similar T2 average relaxation time (251 ms).](image2)
Case 2

A 71y old patient with known endometrial cancer. On MRI images, we easily highlighted the endometrial cancer invading the myometrium, but we were not able to exclude an extension into uterine serosa or into a segment of small bowel loop situated nearby. A cleavage plan between the structures could not be revealed on standard T1, T2 sequences and a possible stage IV disease was suggested. The T2* maps showed different relaxation time for endometrial cancer and small bowel. Intraoperative examination of the segment suggested tumor-free small bowel with no further resection needed; a FIGO stage II was attributed (Figure 3 & 4).

Figure 3: Upper images: Sagital T2 with TE=30ms (left) and TE=200ms (right). Lower images: Proton density map (left) and T2* relaxometry map (right). Enlarged uterus cavity due to proven endometrial carcinoma with deep myometrial invasion. Small bowel loop (arrow) lies tangent to the posterior uterine wall.

Figure 4: Small bowel loop (top) and endometrial cancer (bottom), with different T2* relaxometry values (174 ms versus 347 ms).

Case 3

A 51y old patient with proven cervical cancer. Pelvic MRI was performed for staging purposes. The cervical cancer invades the upper two-third of vagina and has bilateral parametrial involvement. However, the rectum invasion could not be excluded on standard MRI sequences, so the stage IV could not be excluded. On T2* relaxation maps, cervical cancer and the rectum located adjacent to the tumor presented with different value of relaxation times. Intraoperative examination of the rectum excluded a tumoral invasion, and pathology concluded a stage IIB cervical cancer (Figure 5 & 6).

Figure 5: Upper images: Sagital T2 with TE=30 ms (left) and TE=200 ms (right). Lower images: Proton density map (left) and T2* relaxometry map (right). The T2 hyperintense cervical cancer (circle) is located in close proximity with the rectum (arrow).

Figure 6: Cervical cancer (top) relaxometry value = 196 ms and rectum (bottom) relaxometry value (160 ms). Note the thin blue-colored tissue interposed in between the rectum and tumor, which represent the intact serous layer (arrow).

Discussions

We obtained T2 relaxometry maps of endometrial and cervical cancer patients, in axial and sagittal planes, with a larger FOV and shorten acquisition time than previously mentioned [9,10]. We demonstrated T2 relaxometry values of endometrial and cervical cancer, metastatic lymphadenopathy, small bowel and rectum (Table 1).

In first case, the T2* relaxometry values matched the value of the primary tumour (endometrial cancer). This observation could result in a first future oncology prospective, implying that the role of T2 relaxometry maps in identifying metastatic lymph nodes should be investigated and perhaps it may help the radiologist reach a higher confidence in reporting them. In addition, a recent paper addressed the noninvasive characterization of lymph nodes using a multigradient echo signal decay technique, and obtained promising results [14].

In second and third cases, T2* relaxometry values of cancers were different from that of non-cancerous small bowel and rectum confirmed by the intraoperative examination. A second research direction may be suggested related to parametric
maps in patients with doubtful tumor invasion (primary tumor, relapse, adhesions on a postoperative pelvis, or just the lack of the cleavage plan between structures).

Differentiating between endometrial and cervical origin before surgery is critical as it has major implications for patient management. Currently, on MRI, the origin is subjectively established by: 1- the location where the tumor seems to be centered or 2 - the location of the bulk (>50% of the tumor mass) in cases where the tumor extends across the corpus or cervix. Accordingly, we observed different T2* relaxometry values for endometrial and cervical cancer (~300 ms versus 196 ms). A third prospective and future research direction may result from analyzing the current technique on being able to differentiate between endometrial and cervical cancer, based on a cut-off T2* value, especially in patients where biopsy is not possible (eg. cervical stenosis).

### Table 1: T2* relaxometry and proton density values.

<table>
<thead>
<tr>
<th>Area of interest</th>
<th>T2 min (ms)</th>
<th>T2 max (ms)</th>
<th>T2 av (ms)</th>
<th>Std dev</th>
<th>1H min</th>
<th>1H max</th>
<th>1H av</th>
<th>std dev</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endometrial cancer</td>
<td>212.05</td>
<td>581.21</td>
<td>334.96</td>
<td>53.64</td>
<td>104.32</td>
<td>153.6</td>
<td>127.13</td>
<td>7.71</td>
</tr>
<tr>
<td>Cervix cancer</td>
<td>138.48</td>
<td>239.85</td>
<td>196.87</td>
<td>15.7</td>
<td>107.62</td>
<td>130.38</td>
<td>123.8</td>
<td>3.5</td>
</tr>
<tr>
<td>Small bowel loop</td>
<td>112.77</td>
<td>307.32</td>
<td>180.58</td>
<td>29.52</td>
<td>65.81</td>
<td>163.85</td>
<td>105.48</td>
<td>15.79</td>
</tr>
<tr>
<td>Rectum</td>
<td>139.51</td>
<td>187.65</td>
<td>160.64</td>
<td>10.21</td>
<td>97.14</td>
<td>157.95</td>
<td>114.41</td>
<td>9.43</td>
</tr>
</tbody>
</table>

*Minimum, maximum and average T2* relaxometry values (T2 min, T2 max, T2 av) together with standard deviation (Std dev) are presented. Minimum, maximum and average proton density (1H min, 1H max, 1H av) together with standard deviation (std dev), for each examined structure.

### Limitations

First, a too small number of patients have prevented us from establishing a cut-off T2* relaxometry value for each pelvic structure (bladder, vagina, etc.) and/or cancer type. Second, DWI/ADC map were inconclusive for the first out of the three cases and contrast-enhanced sequences were not available for any of the cases.

Emphasizing that the small number of patients didn’t allow us to make a final conclusion supported by statistical analysis, the present article proposes a number of future oncology prospective that could lead to at least two innovative research directions: 1) establishing cut-off values that could be further used to early diagnose the endometrial and cervical cancer or establishing tumor’s origin in selected cases, to identify malignant lymphadenopaties and tumor invasion in the nearby organs; 2) comparing T2* maps with the DWI/ADC and/or contrast-enhanced sequences regarding lymphadenopathy characterization and tumor-invasion. Further studies on larger cohort of patients are needed in order to conclude on and extrapolate the above mentioned concepts and innovative technique.

### References